Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegtarazimod - ReAlta Life Sciences

Next Previous
X
Search
Drug Profile

Pegtarazimod - ReAlta Life Sciences

Alternative Names: RLS 0071; PA-dPEG24 - ReAlta Life Sciences; PIC1-01; PIC1-dPEG24

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReAlta Life Sciences
  • Class Anti-inflammatories; Anti-ischaemics; Antiasthmatics; Antivirals; Neuroprotectants; Peptides
  • Mechanism of Action Antioxidants; Complement C1 inhibitors; Extracellular trap inhibitors; Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Brain hypoxia-ischaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Brain hypoxia-ischaemia; Chronic obstructive pulmonary disease; Graft-versus-host disease
  • Phase I Asthma
  • Preclinical Acute radiation syndrome
  • No development reported Acute lung injury

Most Recent Events

  • 08 Dec 2024 Pharmacodynamics data from preclinical trial in Acute graft-versus-host disease released by ReAlta Life Sciences
  • 19 Aug 2024 Phase-II clinical trials in Graft-versus-host disease (In adolescents, In adults, In the elderly, Treatment-resistant) in Spain, Germany (unspecified route)
  • 19 Aug 2024 Phase-II clinical trials in Graft-versus-host disease (In adolescents, In adults, In the elderly, Treatment-resistant) in USA (unspecified route) (NCT06343792)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top